Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation

✍ Scribed by Kanda, Yoshinobu; Akiyama, Hideki; Tanikawa, Shu; Sakamaki, Hisashi; Sasaki, Tsuneo; Takamoto, Shigeru; Onozawa, Yasusuke; Team, Bmt

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 382 KB
• Volume: 51
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/(sici)1096-8652(199604)51:4<265::aid-ajh3>3.0.co;2-u

✦ Synopsis

To increase the efficacy of bone marrow transplantation (BMT), we have tried to add etoposide (VP-16) to busulfanlcyclophosphamide (BU/CY). Welve patients received 16 mgkg of BU and 120 mgkg of CY with 15-30 mgkg of VP-16. Another two patients received 5 Fgkg of G-CSF with 30 mgkg of VP-16. Patients tolerated escalating doses of VP-16 without any significant hepatotoxicity. Their maximal level of bilirubin was 37.6 FmoVL (2.2 mgldl), and there was no significant skin toxicity or mucositls. By contrast, two patients who recelved G-CSF with 30 mgkg of VP-16 developed hyperbilirubinemla and veno-occlusive disease, which terminated this phase I study. VP-16 can be safely combined with BUlCY 530 mgkg in three divided doses, and Its effect on survival should be evaluated. G-CSF added to thls regimen, however, should be used with great caution. o 1898 wkYdiU, Inc.